The Lancet Haematology/X
Jun 13, 2025, 23:21
Paul J Bröckelmann Shares The Lancet Haematology Commission Update on Adverse Events at EHA 2025
The Lancet Haematology shared a post on X:
“Today at EHA2025 Dr Paul J Bröckelmann shared insights from The Lancet Haematology Commission on Adverse Events.
Our 2025 Series updates priority areas on measuring and managing toxicities in new haematology treatment.”
Paul J Bröckelmann presented updates from The Lancet Haematology Commission’s 2025 Series at EHA 2025, focusing on improving how adverse events are measured and managed in modern haematology therapies.
You Can Find More Posts on Hemostasis Today.
-
Sep 24, 2026, 18:43Hugh Nguyen: Honored to Accept the Friend of Singapore Red Cross Award
-
Sep 24, 2026, 18:42Titilope Fasipe: Proud to Support American Society of Hematology’s SCD Initiative
-
Sep 24, 2026, 18:34Ifeanyichukwu Ifechidere: Why Coagulation Samples Can Be “Too Valuable to Throw Away”?
-
Sep 24, 2026, 18:33Aswin K. Mohan: When a Superpower Hears the Call for Blood
-
Sep 24, 2026, 18:31Mercy Lung’aho: Anemia Is Not Only An Iron Problem
-
Sep 24, 2026, 18:29Nick Hanson: Before a Dementia Diagnosis Check Vitamin B12
-
Sep 24, 2026, 18:28Rachel McBryan: Nearly One in Five Older Canadians Has Low Vitamin B12
-
Sep 24, 2026, 18:27Kemal Karaagac: Early DOAC Initiation After Acute Ischaemic Stroke in Atrial Fibrillation
-
Sep 24, 2026, 18:26Mohammed A. AlOmar: What Characterizes Young Stroke in the UAE?